Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The dose-survival curve of cultured melanoma cells was changed by post-irradiation treatment with 2,4-dinitrophenol (DNP). The parameters of the curves were Do = 147 R and n = 5 . 6 for untreated cells and Do = 143 R, n = 7 . 9 and Do = 142 R, n = 2 . 0 for the cells treated with 10(-5) M DNP and 5 x 10(-5) M DNP in phosphate-buffered saline, respectively. The content of ATP in the cell decreased to 5% of the control level after treatment with either concentration of DNP. The recovery of ATP content was rapid and complete after 2 hours' incubation in culture medium after the removal of 10(-5) M DNP, but was retarded and incomplete after 4 hours with 5 x 10(-5) M DNP. Thus prolonged ATP deprivation with a high concentration of DNP results in an inhibition of recovery and a reduction in the n-value.
 ...
PMID:Alterations in the survival of X-irradiated cells by 2,4-dinitrophenol depending on ATP deprivation. 31 76

This study was designed to study the effect of different fixatives on melanoma antigens by immunofluorescence. Two postautoimmune antimelanoma sera were tested on two human malignant melanoma cell lines fixed with different fixatives by indirect immunofluorescence. Ethanol, methanol, formalin, trichloroacetic acid and acetone gave sharp membrane fluorescence. Minimal to moderate cytoplasmic fluorescence was seen with acetone but none with the others. Formalin gave the highest membrane fluorescent antibody titers at 1/512. Isopentane and isooctane yielded bright cytoplasmic fluorescence. Weak diffuse cytoplasmic fluorescence was seen with glutaraldehyde. Fluorescence was completely abrogated by paraformaldehyde. No fluorescence was seen with four nonimmunized melanoma sera and phosphate-buffered saline when used as controls. It can be concluded that different fluorescent patterns were seen on melanoma cells when different fixatives were used.
 ...
PMID:Effect of different fixatives on the localization of human melanoma antigens by immunofluorescence. 38 7

Clinical interest in the pharmacology of medicinals from marine organisms has heightened due to anticancer effects indicated for Mercenaria marine clam components. This report further characterizes the anticancer principle. Hydrophilic products were extracted by aqueous and/or salting-out methods followed by dialysis. Organic solvent extraction produced a new family of active agents related to the hydrophilic component. Thin layer and liquid column chromatography as well as enzymatic degradation were used to secure a more pure product for analysis. Assay included P388 leukemia and B16 melanoma. Oligonucleotide fractions and smaller components were observed to increase survival rate; treated mice remained at 67% survival when control animals had reached zero. A many-fold purified product was effectively reduced from 300 mg/kg body weight to 5 mg/kg to achieve anticancer activity. Chemical analysis suggested a product composed of carbohydrate, phosphate, peptide, and an unidentified material. Acid hydrolysis revealed the presence of hexoses, pentoses, and a full spectrum of amino acids. Several distinct components found to comprise the active samples may act as the effective product or as a carrier.
 ...
PMID:Chemical characterization and biological activity of an anticancer agent of marine origin. 54 3

Twenty-six patients (14 men and 12 women) with histologically proven advanced malignant melanoma, who previously had not responded to DTIC, methyl-CCNU, and procarbazine, received estramustine phosphate (estracyt) (15 mg/m2) in daily divided doses. All patients had measurable disease. One patient developed a complete remission and one patient had improvement in liver function without measurable regression in the tumor. In three other patients (11%), the disease remained static for a period of 3--5 months. The mean survival time from the beginning of therapy was 16.8 months for the patients with a response or static disease and 2.18 months for those who had no response. Gastrointestinal toxicity was minimal; no hematologic toxicity was observed. It appears that estramustine phosphate used as a single agent for treating advanced malignant melanoma after patients failed to respond to DTIC and to the combination of methyl-CCNU and procarbazine has a poor response rate.
 ...
PMID:Estramustine phosphate in the treatment of advanced malignant melanoma. 68 76

Pigmentation of RVH 421 human melanoma cells is induced when cell division is inhibited by cytochalasin D or L-tyrosine phosphate. Increased pigmentation correlates with increased tyrosinase activity when this is monitored over a time-course. Parallel measurements show that the amount of tyrosinase mRNA correlates with enzyme activity in cells growing without these additives. In contrast, in the presence of cytochalasin D or L-tyrosine phosphate, the increase in amount of tyrosinase mRNA is not sufficient to account for the increase in enzyme activity, indicating that these compounds act mainly at a post-transcriptional level.
 ...
PMID:Induction of tyrosinase in human melanoma cells by L-tyrosine phosphate and cytochalasin D. 137 60

Here we describe a two-step procedure for purification of human tenascin from conditioned medium of the SK-MEL-28 human melanoma cell line. The first step consists in passing the conditioned media through two chromatography columns connected in sequence. The first is a large capacity gelatin--Sepharose affinity chromatography column (to remove fibronectin), the second, over which the unbound material from the first column flows directly, is a hydroxyapatite chromatography column. Under these conditions, all tenascin present in the conditioned medium binds to the hydroxyapatite chromatography column from which it is then eluted by a 5-300 mM sodium phosphate gradient. With this step, we obtain a crude tenascin preparation, concentrated about 20 times with respect to the starting conditioned medium, and in which tenascin represents more than 50% of the total protein. The second step consists of two sequential precipitations with 6% and 12.8% poly(ethylene glycol). After this step, tenascin is more than 95% pure and does not show any contamination of chondroitin-sulfate-containing proteoglycans that are known to bind to it. From 21 medium we obtain about 3-4 mg tenascin which corresponds to a yield of about 40-50%. This procedure gives a higher yield, is simpler with respect to procedures previously described, avoids the exposure of the protein to denaturing agents or harsh conditions and could be used for purification of tenascin from the conditioned media of other cell lines. Thus, this procedure may represent a simple and useful tool for the preparation of tenascin to study its biological functions.
 ...
PMID:A simple procedure for tenascin purification. 137 29

The cyclopropylpyrroloindole analogues are DNA minor-groove binders containing a cyclopropyl group, which mediates N3-adenine covalent adduct formation in a sequence-selective fashion. Carzelesin (U-80244) is a cyclopropylpyrroloindole prodrug containing a relatively nonreactive chloromethyl precursor to the cyclopropyl function. Activation of carzelesin requires two steps, (a) hydrolysis of a phenylurethane substituent to form U-76073, followed by (b) ring closure to form the cyclopropyl-containing DNA-reactive U-76074. The formation of the DNA-reactive U-76074, via U-76073, from carzelesin was shown to proceed very slowly in phosphate-buffered saline (t1/2 greater than 24 h) but to occur rapidly in plasma from mouse, rat, dog, and human (initial t1/2 values ranging from 18 min for mouse to 52 min for rat) and in cell culture medium (t1/2 approximately 40 min). Although carzelesin was less potent in terms of in vitro cytotoxicity and in vivo optimal dosage and showed low affinity for binding to DNA, it was therapeutically more efficacious against mouse L1210 leukemia than was U-76074 or adozelesin (U-73975), another cyclopropylpyrroloindole analogue which is currently in phase I clinical trials. Carzelesin also proved to be more efficacious than U-76074 or adozelesin against mouse pancreatic ductal 02 adenocarcinoma, a system reported to be resistant to every agent tested. Carzelesin was highly effective against this tumor and produced 97% tumor growth inhibition. In addition, i.v. administered carzelesin showed significant activity (National Cancer Institute criteria) against i.v. or s.c. implanted Lewis lung carcinoma, i.p. or s.c. implanted B16 melanoma, s.c. implanted colon 38 carcinoma, and five s.c. implanted human tumor xenografts, including clear cell Caki-1 carcinoma, colon CX-1 adenocarcinoma, lung LX-1 tumor, ovarian 2780 carcinoma, and prostatic DU-145 carcinoma. Carzelesin treatment produced 100% complete remissions (no palpable tumor mass at the termination of the experiment) in mice bearing early-stage human ovarian 2780. Pharmacologically, carzelesin proved to be relatively schedule and route independent and was highly active against i.p. implanted L1210 leukemia, regardless of whether the analogue was given i.v., i.p., s.c., or p.o. These results, collectively, suggest that carzelesin is absorbed and distributed well. Both carzelesin and adozelesin caused marked tumor shrinkage in mice bearing human lung LX-1 or advanced-stage human ovarian 2780 carcinoma; however, tumor regrowth occurred shortly after the treatment with adozelesin was stopped. Little or no apparent tumor regrowth occurred after treatment with carzelesin.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. 151 47

It has been shown that alpha-MSH inhibits the growth of amelanotic cells of human malignant melanoma (BRO) without their melanization or the expression of tyrosinase activity. alpha-MSH changed the activity of cytosol and microsomal forms of phosphatidyl inositol kinase and phosphatidyl inositol-4-phosphate kinase determining the concentration of phosphatidyl inositol-4-phosphate and phosphatidyl inositol-4,5-bisphosphate. It also induced an "outburst" in the levels of myo-inositol phosphates (mono-, bis- and 1,4,5-trisphosphates). Changes in the levels of myo-inositol phosphates occurred within seconds, and are suggested to play a certain part in the hormonal regulation of melanoma cell growth.
 ...
PMID:Melanocyte-stimulating hormone (alpha-MSH) inhibits the growth of human malignant melanoma cells with the induction of phosphatidyl inositol and myo-inositol phosphate levels. 166 68

Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite appropriate dose escalation. Myelosuppression occurred without significant sequelae.
 ...
PMID:Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study. 170 51

Chilled B16CL4 mouse melanoma cells in phosphate-buffered saline were exposed to ionizing radiation before or after harvesting by gently scraping with a rubber policeman. Cells irradiated when attached had fewer DNA strand breaks than cells that were irradiated in suspension. Dose-response studies indicate that the rate of induction of DNA strand breaks by ionizing radiation is 1.5-fold greater in suspended cells. Irradiation after release of the cells by trypsinization also results in more breaks than irradiation when attached, but this method of harvest is not as damaging as release by rubber policeman. Strand breaks in unirradiated cells are unaffected by the method of cell harvest. These studies suggest that, in radiation studies, care should be exercised to avoid the introduction of artifacts resulting from the methods used to harvest and irradiate cells.
 ...
PMID:Irradiation of cells attached or suspended by rubber policeman or by trypsin influences the extent of DNA strand breaks induced by ionizing radiation. 200 Apr 59


1 2 3 4 5 6 7 8 9 10 Next >>